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Alzheimer’s disease (AD) is the most prevalent form of dementia. Biomarkers such as levels of amyloid beta (Aβ) in cerebrospinal 
fluid and ApoE genotyping were suggested for the diagnosis of AD, however, the result is either non-conclusive or with invasive 
procedure. Genome-wide association studies (GWASs) for AD suggested single nucleotide polymorphisms (SNPs) in many genes 
are associated with the risk of AD, but each only contributed with small effect to the disease. By incorporating a panel of estab-
lished genetic susceptibility factors, the risk of an individual in getting AD could be better estimated. Further research will be 
required to reveal if adding to the current well-developed clinical diagnosis protocol, the accuracy and specificity of diagnosis 
of AD would be greatly improved and if this might also be beneficial in identifying pre-symptomatic AD patients for early diagnosis 
and intervention of the disease.
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INTRODUCTION
　Alzheimer’s disease (AD) is the most prevalent form of 
age-related dementia and it is currently affecting more 
than 30 million people worldwide and the number of peo-
ple with AD will have doubled to 46 million by 2020.
1) It 
has been estimated that delaying the mean age of onset of 
AD by about 5 years would reduce the number of in-
dividuals with this disease by 50% by 2050. Mild cogni-
tive impairment (MCI) is a clinical diagnosis for in-
dividuals who have cognitive deficits but do not fulfill the 
diagnosis of dementia that may represent the early stage of 
AD.
2-4) Studies showed that the annual conversion rate for 
individuals with MCI to AD is 10-12%, compared to the 
conversion rate of 1-2% in the normal elderly popula-
tion.
3) Therefore, early detection of AD and accurate pre-
diction of progression from MCI to AD are the important 
areas of research in AD.
　Over the past decades, basic and clinical research stud-
ies provided a lot of knowledge on the molecular mecha-
nism and the clinical progression of the disease. AD is 
characterized by the deposition of amyloid plaques com-
posed of amyloid beta-peptides (Aβ) derived from amy-
loid precursor protein (APP) and the formation of neuro-
fibrillary tangles composed of hyperphosphorylated tau.
5) 
AD is mainly classified into two groups: (1) early-onset 
AD, which accounts for 1-6% of all cases and has its onset 
before the age of 65 years, and (2) late-onset AD, which is 
responsible for the vast majority (94-99%) of cases and 
symptoms appear after 65 years old. Several causative 
mutations on APP, presenilin 1 (PSEN1) and presenilin 2 
(PSEN2) have been identified in familial type AD.
6) On 
the other hand, late-onset AD is a complex neuro-
degenerative disease and it is caused by genetic and envi-
ronmental risk factors. 
DIAGNOSIS OF AD
　The diagnosis of AD is based on clinical examination 
using criteria of the National Institute of Neurological and 
Communicative Disorders and Strokes and the Alzhei-
mer’s Disease and Related Disorders Association Work 
Group (NINCDS-ADRDA).
7) The diagnostic criteria are 
well-established and have high reliability and consis-
tency.
8,9) Definitive diagnosis of AD can only be achieved 
by postmortem examination based on the histopathologic Genetic Biomarker 55
confirmation. Although the diagnostic criteria have good 
reliability and validity, it is not designed to identify pa-
tients with very mild symptoms or to assess the probability 
of conversion from MCI to AD. 
BIOMARKERS
　In the past decades, a large number of independent stud-
ies were carried out to evaluate the use of biomarkers in fa-
cilitating reliable diagnosis of AD, even in the preclinical 
stage. Based on the pathological importance of amyloid 
plaques and neurofibrillary tangles on AD, the levels of A
β40, Aβ42, total tau and phosphorylated tau (p-tau) in 
cerebrospinal fluid (CSF) have emerged as the major bio-
markers of interest.
10-14) Aβ40 and Aβ42 are produced 
from APP cleavage pathway. Based on the observation 
that increased production of Aβ42 in missense mutations 
in the APP, PS1 and PS2 genes which cause familial AD, 
suggesting Aβ42 plays a central role in the pathogenesis 
of AD.
15) Studies suggested that the concentration of Aβ
42 in CSF is significantly lower in AD patients when com-
pared to the age-matched normal controls.
16) On the other 
hand, total tau in CSF reflects the formation of neuro-
fibrillary tangles in AD. Elevated level of total tau in AD 
patients have been reported and reviewed in a meta-analy-
sis study.
14,17-19) However, elevated level of total tau in 
CSF is not a specific marker for AD as it is also observed 
in fronto-temporal dementia (FTD),
10) vascular de-
mentia
20) and acute ischemic stroke. On the other hand, 
p-tau is a more specific biomarker for AD as elevated level 
of p-tau is only detected in AD but not other neurological 
diseases such as Lewy body dementia and FTD.
21,22)
　The National Institute on Aging Working Group out-
lined several criteria for an ideal diagnostic biomarker in-
cluding fundamental relatedness to the disease, vali-
dation, high sensitivity and specificity. Also, the bio-
markers should be noninvasive, inexpensive and readily 
available.
23) However, sampling CSF requires the lumbar 
puncture which is an invasive procedure and the cost for 
CSF testing is expensive.
IMAGING
　Recent advances in functional and molecular neuro-
imaging provided insights into brain structure and 
physiology. Imaging techniques such as magnetic reso-
nance imaging (MRI), functional MRI (fMRI), magnetic 
resonance spectroscopy (MRS) and positron emission to-
mography (PET) provided information on the regional 
changes of the brain in AD patients when compared to 
normal age-matched controls. MRI can be used to meas-
ure the degree of atrophy and it provided information on 
the disease state and progression. MRI-based atrophic 
changes are well matched with the pathological changes 
of tau deposition.
24-27)
　Microstructural changes such as loss in dendrites, mye-
lin and axon in AD can be detected by MRS.
28) Combining 
the use of radiological-contrast compounds and imaging 
techniques, some promising diagnostic tool has been 
studied. One of the widely studied amyloid-binding com-
pounds is 
11C-PIB (PIB, Pittsburgh compound B). The up-
take of PIB was measured by PET and AD patients 
showed specific retention of PIB in regions of the brain 
which is corresponded to the location of amyloid 
deposition.
29) However, there was also studies reporting 
elderly subjects without MCI showing increased uptake of 
11C-PIB
30,31) but it is uncertain whether this imaging mark-
er has prognostic implications on AD. 
GENETIC STUDIES IN AD
　ApoE is a widely accepted genetic risk factor for 
late-onset sporadic AD. Studies showed that ε4 allele in-
creased AD risk in a dose-dependent manner while ε2 al-
lele has a protective effect on AD.
32-34) However, bearing 
ε4 allele is neither sufficient nor necessary for the devel-
opment of AD. Many linkage studies were performed to 
identify the chromosome/loci associated with the risk of 
AD and identified the ApoE region on chromosome 19 as 
the risk locus for AD.
35-37) This provided further evidence 
for the association of ApoE and the risk of AD. On the oth-
er hand, several linkage studies identified other regions on 
chromosome 6,
35,36,38,39) 9,
35,36) 10
35,39,40) and 12
41,42) other 
than chromosome 19 to be associated with the risk of AD, 
suggesting genes other than ApoE are involved in the ge-
netics of this complex disease. These linkage studies not 
only providing further evidence of the involvement of 
multiple chromosomal regions to the association of the 
risk of AD, it provided the bases for the individual candi-
date gene studies. One of the example is tumour necrosis 
factor-α  (TNFα), which is located on chromosome 6p21 
and it was identified by several linkage studies to be sig-
nificantly associated with the risk of AD.
36,38,39,41) Genetic 
association studies also showed significant association of 
TNFα  polymorphism and the risk of AD.
43-47)
　With the advance of genotyping technology and the 
launching of International HapMap project,
48) many large 
scale genome-wide association studies (GWASs) were 56 S.L. Ma and L.C.W. Lam
Table  1.  Summary  of  results  of  genome-ide  association  study  in  AD
Studies AD Normal Gene p v a l u e Odds ratio
Grupe  et  al.
190)
Li  et  al.
128)
Abraham e t  a l .
191)
Bertram e t  a l .
192)
Beecham  et  al.
193)
Feulner  et  al.
194)
Harold  et  al.
50)
Lambert  et  al.
51)
Seshadri  et  al.
87)
1808
 7 5 3
1082
1376
 7 3 0
 4 9 1
4957  (Stage  1)
2023  (Stage  2)
2032  (Stage  1)
3978  (Stage  2)
3006  (Stage  1)
2032  (Stage  2)
2062
 7 3 6
1239
 7 1 8
 4 7 9
9682  (Stage  1)
2340  (Stage  2)
5328  (Stage  1)
3297  (Stage  2)
14642  (Stage  1)
5328  (Stage  2)
TOMM40,  ApoE,  GALP,  TNK1,  APOC2, 
PCK1,  LMNA,  PGBD1,  THEMS,  MYH13, 
C T S S ,  U B D ,  B C R ,  A G C 1 ,  T R A K 2 ,  E B F 3
GOLPH2
LRAT
chr  14q31,  chr19q13
chr  12q13
MAPT, SORL1, CHRNB2, CH25H, GAB2, 
PGBD1,  PCK1,  LMNA
CLU,  PICALM
CLU,  CR1
BIN1, EXOC3L2/BLOC1S3/ MARK4, CLU, 
PICALM
0.001  to  1.0×10
−8
9.82×10
−3
3.4×10
−6 t o  6 . 1 ×10
−7
6.0×10
−6 t o  2 . 0 ×10
−6
3.4×10
−7
0.05  to  6.8×10
−3
1.3×10
−9  to  8.5×10
−10
3.7×10
−9  to  7.5×10
−9
0.007  to  0.03
1.07  to  2.73
0.51
1.2  to  1.3
1.1  to  1.4
−
−
0.86
0.86  to  1.21
0.82  to  1.26
AD,  Alzheimer's  disease;  CLU,  clusterin.
performed to investigate the genes associated with the risk 
of AD. GWASs simultaneously genotyped a large number 
of genetic markers in a unbiased setting as the single nu-
cleotide polymorphisms (SNPs) to be genotyped were 
chosen to cover the common variations in human 
genome.
49) Until now, more than 10 AD GWASs were per-
formed and a number of candidate genes for the risk of AD 
were identified. The results from the GWASs of AD were 
summarized in Table 1. Individual genetic association 
studies were also performed to follow-up and validate the 
findings from GWASs in different populations. Intere-
stingly, these GWASs identified different candidate genes 
for the risk of AD but they consistently resulted in sig-
nificant association of Apolipoprotein E (ApoE) and the 
risk of AD. Recent GWASs identified three genes includ-
ing CLU, CR1 and phosphatidylinositol binding clathrin 
assembly protein (PICALM) as the susceptibility genes 
for AD.
50,51)
　Since the identification of the association of ApoE and 
the risk of AD, it remains to be the most widely studied 
gene in AD. AlzGene website (http://www.alzgene.org)
33) 
is a database with continuously updated list of genes asso-
ciating with AD. The database provided the results of al-
lele-based meta-analyses for all polymorphisms with suf-
ficient genotype data and ranked the genes based on the 
genetic variant with the strongest association (HuGE-
Net/Venice criteria, p-value and effect size) to AD. In the 
database, there is a “Top Results” list showing the “most 
promising” AD candidate genes and it could help in 
choosing the genes in high priority for future studies. 
However, there is unavoidable limitation of the database 
such as possibility in overlooking the studies, allele analy-
sis instead of genotype analysis (less powerful in reveal-
ing the underlying mode of inheritance), lack of haplotype 
data or consideration of co-variates such as age or gender. 
According to the statistics of AlzGene as of October 2010, 
the top ten genes showed the strongest association in AD 
are ApoE, CLU, PICALM, EXOC3L2, BIN1, CR1, 
SORL1, GWA_14q32.13, TNK1 and IL8. 
GENETIC VARIATIONS AS MARKERS 
FOR ALZHEIMER’S DISEASE
　Results from GWASs and linkage studies in AD identi-
fied several genes/SNPs conferring to the risk of AD. In 
addition, twin studies suggested that the additive genetic 
effects contributed 37% to 75% to the variance in 
age-at-onset of AD.
52) On the other hand, it is uncommon 
to have large implication of a single gene in common dis-
eases such as AD. For most genes or SNPs, they only con-
ferred a modest risk to the disease. It is unlikely that any 
single genetic polymorphism would be sufficient to be a 
reliable marker as diagnostic and prognostic tool, but a 
panel of genetic variation markers might serve this 
purpose. Recently, a study reporting 95 loci associated 
with lipid traits was based on analyzing the result of 59 
GWAS,
53) which made the idea of developing a panel of 
genetic marker as diagnostic and prognostic tool for AD 
promising. In this review, the relatedness and usefulness 
of using genetic variations in AD susceptibility genes as 
diagnostic tool and markers will be discussed.  
ApoE
　ApoE gene is mapped to chromosome 19q13.2 and it is 
expressed in liver, brain and cells such as macrophages 
and monocytes.
54) There are three isoforms of ApoE cod-
ed for by ε2, ε3 and ε4 alleles. A dose-dependent ef-
fect of ApoE ε4 and the risk of AD was reported in 
late-onset AD
34) and the finding was replicated by differ-Genetic Biomarker 57
ent groups in different populations.
32,55-58) It is by far the 
most widely studied and replicated genetic polymorphism 
conferring to the risk of AD, up to 20-50%.
59) Bearing ε4 
allele increased the risk for AD from 20% to 90% and de-
creased the age-at-onset from 84 to 68 years with an in-
creased dose of ApoE ε4 alleles.
34,60) Moreover, bio-
chemical data showed ApoE was associated with amyloid 
in senile plaques
61) and neurofibrillary tangles.
62,63) 
Different isoforms of ApoE bind Aβ  in different rate and 
ε4 binds to Aβ  at a faster rate when compared to ε3.
64) 
On the other hand, both ApoE ε2 and ε3 bind to tau pro-
tein but not ε4, suggesting the interaction between ApoE 
and tau may serve as a protective function and this might 
explain the biological significance of ε4 as a risk factor 
for AD. Until now, almost all GWASs in AD identified 
ApoE as a susceptibility locus and the association of ApoE 
ε4 and the risk of AD was replicated and confirmed in 
large number of studies in different populations. 
　There is a dose-dependent effect of ApoE and the risk of 
AD where 55% of ApoE ε4/ε4 group developed AD, 
compared with 27% of ApoE ε3/ε4 and 9% of ApoE ε3/
ε3 groups.
65) The frequency of ε4 is less than 20% com-
pared to ε3, with a frequency of over 65%,
66) therefore it 
is unlikely the genotype of ApoE alone is sensitive enough 
to diagnose AD. It is clear that bearing ApoE ε4 allele in-
creased the risk of AD but not essential for the develop-
ment of AD. Several studies assessed the specificity and 
sensitivity of ApoE genotyping in the diagnosis of AD. 
The sensitivity of ApoE genotyping for the diagnosis of 
AD varied and it ranged from 19% to 75%.
67-70) Mayeux et 
al.
68) assessed the specificity and sensitivity of ApoE gen-
otyping, clinical diagnosis and the combination of both 
techniques in more than 2000 AD patients. They reported 
the specificity of clinical diagnosis and ApoE genotyping 
alone were 55% and 68% respectively, although the sensi-
tivity of clinical diagnosis was much higher than ApoE 
genotyping, with 93% versus 65%. They further analysed 
the specificity of combining both techniques and it in-
creased to 84%, suggesting the combination of clinical di-
agnosis and ApoE genotyping would greatly reduce the 
false positive rate. Overall, the specificity of clinical diag-
nosis and ApoE genotyping were 50-55% and 68-71% re-
spectively
68,71) but the sensitivity of ApoE genotyping was 
much lower than clinical diagnosis, with only 59-65% 
compared to clinical diagnosis yielding up to 93%. The 
specificity of diagnosis with both clinical diagnosis and 
ApoE genotyping was greatly increased to 84%, which 
was higher than either method alone. A study examining 
the predictive value of ApoE genotyping in 69 patients 
who had been clinically diagnosed with probable AD and 
85% of them were confirmed to have AD at autopsy. No 
non-AD demented patients were found to carry ApoE ε4 
allele and 75% autopsy-confirmed AD patients carried at 
least one ε4 allele, which gave a 100% specificity of 
ApoE genotyping in predicting AD.
67) However, there was 
also study showing that 50% of individuals carrying at 
least one ε4 allele did not develop AD in their lifetime.
72) 
Therefore, ApoE genotyping alone does not have suffi-
cient specificity and sensitivity for the diagnosis of AD 
but it might be used as a adjutant test to improve the accu-
racy of clinical diagnosis of AD.
CLU
　Clusterin (CLU), also named as apolipoprotein J, is 
mapped on chromosome 8. Like ApoE, it is a lipoprotein 
that widely expressed in most tissues, with higher levels in 
brain, liver, ovary and testis.
73) Owing to its functional re-
lationship with ApoE, it is a candidate gene for the risk of 
AD. In addition, several lines of evidence suggested its 
role in the pathogenesis of AD. It was shown that the CLU 
expression was elevated in hippocampus, both in AD pa-
tients and animal models.
74-76) CLU has a regulatory role 
in Aβ  metabolism, that it binds to soluble Aβ,
77-80) pre-
vents aggregation of Aβ
79,80) and suppresses Aβ  deposi-
tion and modifies Aβ  clearance together with ApoE.
81-83) 
Studies also showed that reduced levels of ApoE and in-
creased levels of CLU were associated with the number of 
ApoE ε4 allele, suggesting a compensatory effect of 
CLU on the reduced level of ApoE.
84) The association of 
CLU polymorphism rs11136000 and the risk of AD was 
recently identified by two lately published large scale 
GWASs.
50,51) These two papers were followed by other in-
dividual genetic association studies, including meta-anal-
ysis studies from different cohorts of different populations 
confirming the association.
85-88) A recent study showed as-
sociation of disease progression and severity of AD and 
the plasma concentration of CLU, although they showed 
no association of the SNP rs11136000 and the risk of 
AD.
89) Polymorphism of CLU has also been reported to be 
associated with serum HDL cholesterol.
90) With the sim-
ilarities of the function of CLU and ApoE and their sig-
nificant association to the risk of AD, the importance of 
lipid metabolism and trafficking in brain became an area 
for research in AD. 58 S.L. Ma and L.C.W. Lam
PICALM
　PICALM, encodes the phosphatidylinositol-binding 
clathrin assembly protein and is mapped on chromosome 
11.
91) It is ubiquitously expressed and it is highly ex-
pressed in neurons. PICALM is involved in clathrin-medi-
ated endocytosis
92) and in the fusion of synaptic vesicles to 
the presynaptic membrane by directing the trafficking of 
VAMP2 involved in neurotransmitter release.
93) The asso-
ciation of genetic variation in PICALM and the risk of AD 
was first identified through GWAS by Harold et al.
50) and 
the result was further replicated and confirmed by other 
individual groups and meta-analysis.
85,87,88)  The SNP 
rs3851179, 88.5kb 5’ to PICALM was associated to the 
risk of AD. The polymorphism might alter the function of 
PICALM in synaptic vesicle cycling or endocytic path-
ways resulting in changes in APP processing and Aβ 
levels.
50) Meta-analysis study by Jun et al.
85) showed there 
was synergistic effects of ApoE and PICALM on AD risk 
and such synergistic effect was also identified by previous 
studies investigating interaction of ApoE with PSEN1,
94) 
PSEN2
95) and APP.
95,96) In addition, PICALM SNP 
rs3851179 was associated with hippocampal volume and 
entorhinal cortex thickness (ECT).
97) Biochemical studies 
showed that PICALM is localized at the endothelial cell of 
brain and this facilitates the transportation of Aβ  across 
the blood vessel wall as the major pathway for Aβ 
removal. Polymorphisms of PICALM might increase the 
expression of PICALM and impaired the Aβ removal 
mechanism, which ultimately causing the development of 
AD.
98)
CR1
　CR1 encodes complement component (3b/4b) receptor 
1 and is mapped to chromosome 1q32. The hypothesis on 
the relationship between inflammation/immune response 
and the development of AD was proposed for decades. 
Several lines of evidence including activated microglia 
surrounding Aβ deposits as phagocytic response acti-
vated by Aβ  in microglia in a dose- and time-dependent 
manner,
99) the release of various inflammatory mediators 
after microglia activation,
100,101) recruitment of astrocytes 
to enhance the inflammatory response against Aβ, acti-
vation of complement cascade and induction of other in-
flammatory components such as inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2),
102,103) 
suggested microglia and astrocytes are the major players 
involved in the inflammation process leading to the devel-
opment of AD.
101,104)
　CR1 plays an important role in the regulation of com-
plement cascade and clearance of complement compo-
nents C3b and C4b.
105) Several lines of evidence including 
activation and bounding of Aβ  by C3b,
106-108) inverse re-
lationship between C3b expression and Aβ deposi-
tion
109,110) and C3b deficiency in APP transgenic mice re-
sulted in Aβ accumulation and neurodegeneration
109) 
suggested the involvement of C3b in the pathogenesis of 
AD. Since CR1 is the receptor for C3b and a protective 
role for CR1 in AD through the binding of C3b and sub-
sequent Aβ clearance was suggested.
51,111) A recently 
published GWAS of AD showed significant association of 
CR1 polymorphism rs3818361 and the risk of AD
51) and it 
was replicated and confirmed by other independent 
studies.
85,88) In addition, another CR1 SNP rs1408077 was 
associated with ECT,
97) suggesting the biological rele-
vance of this gene and the risk of AD.
SORL1
　SORL1 encodes sortilin-related receptor 1 and is map-
ped on chromosome 11q23. SORL1 is a member of the 
low density lipoprotein receptor family of ApoE receptors 
in human brain.
112) Studies showed that reduced SORL1 
expression in AD patients
113,114) and human brain cells,
115) 
suggesting the possible relationship of SORL1 and the 
pathogenesis of AD. It was identified that SORL1 is in-
volved in the processing and trafficking of APP, by bind-
ing directly to APP and sorting it into endocytic or re-
cycling pathways, thus influencing Aβ  generation.
116,117) 
In the absence of SORL1, APP entered the endosomal 
pathway and subjected to β- and γ-secretases cleavage 
and resulted in Aβ  production. 
　The association of genetic polymorphisms of SORL1 
and the risk of AD was identified
118,119) and confirmed in 
different populations.
120-124) In addition, SORL1 was iden-
tified in GWAS of AD
125) and provided further evidence of 
its role in the risk of AD. The first study reporting the asso-
ciation of SORL1 SNPs and the risk of AD was performed 
in multi-centers setting and they included four different 
ethnic groups. The authors identified two sets of hap-
lotypes: SNPs in the 5’end and SNPs in the 3’ end and their 
biological study suggested that the genetic variants might 
modulate the cell-type specific transcription or translation 
of SORL1 in neurons.
119) The association of SNPs in 
SORL1 and the risk of AD was further confirmed in au-
topsy-confirmed AD patients.
121) Groups using different 
populations to examine the relationship between SORL1 Genetic Biomarker 59
and the risk of AD, with four supported the initial find-
ings
120,121,126,127) but the other three showed either negative 
or weak results.
122,124,128) One of the studies showed sig-
nificant association of the SORL1 haplotypes and the risk 
of AD and also abstract reasoning ability as measured by 
Similarity test.
126) This finding suggested that poly-
morphisms in SORL1 might be useful in predicting the 
risk of AD, as well as the severity of the disease or the pre-
clinical symptoms of the disease.
INFLAMMATION-RELATED GENES
　As mentioned in previous section, there is hypothesis 
for the important role of inflammation in the pathogenesis 
of AD and genes involved in the inflammatory pathway 
are therefore of high interest as the susceptibility genes for 
AD. Studies showed that microglia surrounding plaques 
was positive for markers related to inflammation such as 
MHC class II, COX-2, MCP-1, TNF-α, IL-1β and 
IL-6.
104) In addition, elevated levels of chemokines and 
cytokines and their receptors including IL-1α, CXCR2, 
CCR3, CCR5 and TGF-β were found in post-mortem 
AD brains.
129) Epidemiological studies suggested 
non-steroidal anti-inflammatory drugs (NSAIDs) might 
be beneficial in preventing or delaying the onset of 
AD,
130,131) but not reversing the pathology.
132) Based on 
these observations and the on-going studies investigating 
the relationship between inflammation and AD, it is hy-
pothesized that Aβ  aggregates trigger microglia and as-
trocytes, leading to local inflammation and further acti-
vate the immune response. This resulted in the activation 
of inflammatory mediators such as TNF-α, IL-1β  and 
IL-6, causing neuronal cell death and further activates mi-
croglia and astrocytes, formed a vicious cycle of in-
flammatory response.
133-135)
　There were many genetic association studies inves-
tigating the relationship of polymorphisms of inflam-
matory-related genes including TNF-α, IL-1β, IL-6, 
IL-10, TLR-4 and COX-2 and the risk of AD. In addition, 
among the top 10 genes as listed in AlzGene, two of them 
are involved in the inflammatory pathway (CR1 and 
IL-8), suggesting the possible implication of in-
flammation in the pathogenesis of AD. Different TNF-α 
SNPs (-238, -308, -850, -863 and -1031) were inves-
tigated in genetic association studies and TNF-238, -863 
and -1031 were reported to modulate the transcriptional 
activity of TNF-α  gene and to be associated with risk of 
AD, with population specificity.
46,47,136-141) AlzGene 
meta-analysis showed that TNF-1031 was significantly 
associated with the risk of AD, giving odds ratio of 1.35 
(95% CI: 1.04-1.77). IL-1β-511 and IL-1β-3953 were 
the most widely studied SNPs in IL-1β  for the risk of AD. 
However, the results of the published genetic association 
studies on the relationship between IL-1β  and the risk of 
AD are still inconclusive.
142-158) AlzGene meta-analysis 
showed that both SNPs were significantly associated with 
the risk of AD and another meta-analysis study confirmed 
the association of IL-1β-3953 but not IL-1β-511.
33,159) 
Di Bona et al.
44) showed a remarkable heterogeneity 
among studies for IL-1β-511, therefore sub- group 
(Caucasians) meta-analysis was performed and yielded 
significant association to the risk of AD, with OR of 1.32 
(95% CI: 1.03-1.69).
44) This finding suggested that there 
is hidden population stratification for some SNPs in the 
association to the risk of the trait and it is important to con-
trol for these variants for the data analysis.
　Many groups performed genetic association studies on 
IL-6 and the risk of AD. The common SNPs for IL-6 being 
studied included -572, -174 and variable number tandem 
repeat (VNTR) polymorphism but there was no confirmed 
association.
160-167) Interestingly, some studies showed no 
association of genetic polymorphisms on IL-6 and the risk 
of AD alone, but observed significantly increased risk of 
AD when combined with certain genotypes at other genes 
such as TNF-α  and IL-10, suggesting there might be in-
teraction effect between genes in modulating the risk of 
AD.
168-170) IL-10 is an anti-inflammatory gene and several 
groups reported association of IL-10 polymorphisms 
and the risk of AD
171-175) but the association is incon-
clusive with some studies reporting negative resul-
ts.
47,128,139,176-178) IL-10 polymorphisms were associated 
with IL-10 levels
175,179) and clinical progression of AD,
180) 
suggesting its possible function as genetic marker for pre-
dicting disease progression. COX-2 is also at the top list of 
the inflammation-related genes implicating in the risk of 
AD, based on its important role in the pathophysiological 
process of inflammatory disease. Polymorphisms of 
COX-2 (-2319, -765, Ex10+837) were associated with the 
risk of AD
181-183) and the use of COX-2 inhibitors has been 
suggested for treatment of AD.
184,185)
　The advantage of using genetic marker for in-
flammatory genes in determining the risk of AD over 
measuring the level of inflammatory cytokines such as 
IL-1, IL-6, IL-10 or TNF-α, is the measurement will be 
less likely to be affected by the daily fluctuation. Several 
studies suggested that the increased level of inflammatory 
cytokines is associated with increased risk of AD. On the 
other hand, several genetic markers were associated with 60 S.L. Ma and L.C.W. Lam
the predisposition of increased inflammatory cytokine 
levels. Therefore, it might be possible to predict one’s risk 
of getting AD by genotyping those inflammatory genetic 
markers.
　As observed in other common diseases, the SNPs asso-
ciated with the risk of AD conferred a small effect to the 
risk of AD, giving the relative risk of the disease to the or-
der of 1.1 to 2.0 and odds ratio rarely exceeding 3.
33,186) For 
example, it is estimated the attributable fraction for ApoE 
was 25.5%, CLU was 8.9% and CR1 was 4%.
51,111) Since 
AD is a complex disease and it is expected to be affected 
by multiple genes and polymorphisms, with each con-
tributing a small effect on the disease risk. On the other 
hand, gene-gene interaction effect for the risk of AD was 
observed in a number of genes such as IL-1, IL-10 and 
TNF-α,
168-170) testing multiple SNPs that were associated 
with the risk of AD might provide more information in the 
prediction.
187) Studies in other common diseases such as 
diabetes also suggested the use of multiple gene loci to 
predict disease risks.
188) Genetic profiling, by incorporat-
ing a panel of established genetic susceptibility factors to 
estimate one’s risk to a disease might be useful in provid-
ing a more accurate diagnosis.
189) Each susceptibility lo-
cus contributed to the genetic risk score can be added up 
and weighed differently based on its prevalence and rela-
tive risk to the disease. For example, the genotype of 
ApoE is expected to be weighted more in the risk score. A 
cut-off score can then be determined base on the results of 
previous studies and algorithm to estimate the risk of the 
disease. In AD, genes showing significant association in 
GWASs of AD, inflammatory genes and ApoE will be 
promising candidate genes for the panel in genetic profil-
ing for diagnosis of AD or predicting one’s risk of con-
version from MCI to AD. However, this approach is lim-
ited by the restricted predictive value of genetic markers in 
complex disease and by the interaction effect of environ-
mental influences such as exposure to different environ-
mental factors and epigenetic changes on the onset and 
progression of the disease. At this stage, genetic profiling 
will not be adequate for the diagnosis of AD but it might 
improve the accuracy and specificity of diagnosis in addi-
tion to the present clinical diagnosis and imaging techni-
ques and possibly applied in the identification of 
pre-symptomatic AD patients. 
　In conclusion, a large collaborative efforts will be re-
quired to explore the genetic variations, including struc-
tural variation and epigenetic, in addition to the statistical 
algorithms to estimate the contribution of each suscepti-
bility polymorphism to the overall disease risk of AD. 
Further research efforts are necessary to find out if in the 
future, genetic profiling in addition to the current clinical 
diagnosis might be useful in identifying subjects with high 
risk of AD predisposition and ultimately lead to early di-
agnosis and intervention of the disease. 
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